Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Ann Rheum Dis ; 81(5): 720-728, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35022159

RESUMEN

OBJECTIVES: The emergence of strains of SARS-CoV-2 exhibiting increase viral fitness and immune escape potential, such as the Delta variant (B.1.617.2), raises concerns in immunocompromised patients. We aimed to evaluate seroconversion, cross-neutralisation and T-cell responses induced by BNT162b2 in immunocompromised patients with systemic inflammatory diseases. METHODS: Prospective monocentric study including patients with systemic inflammatory diseases and healthcare immunocompetent workers as controls. Primary endpoints were anti-spike antibodies levels and cross-neutralisation of Alpha and Delta variants after BNT162b2 vaccine. Secondary endpoints were T-cell responses, breakthrough infections and safety. RESULTS: Sixty-four cases and 21 controls not previously infected with SARS-CoV-2 were analysed. Kinetics of anti-spike IgG after BNT162b2 vaccine showed lower and delayed induction in cases, more pronounced with rituximab. Administration of two doses of BNT162b2 generated a neutralising response against Alpha and Delta in 100% of controls, while sera from only one of rituximab-treated patients neutralised Alpha (5%) and none Delta. Other therapeutic regimens induced a partial neutralising activity against Alpha, even lower against Delta. All controls and cases except those treated with methotrexate mounted a SARS-CoV-2 specific T-cell response. Methotrexate abrogated T-cell responses after one dose and dramatically impaired T-cell responses after two doses of BNT162b2. Third dose of vaccine improved immunogenicity in patients with low responses. CONCLUSION: Rituximab and methotrexate differentially impact the immunogenicity of BNT162b2, by impairing B-cell and T-cell responses, respectively. Delta fully escapes the humoral response of individuals treated with rituximab. These findings support efforts to improve BNT162b2 immunogenicity in immunocompromised individuals (ClinicalTrials.gov number, NCT04870411).


Asunto(s)
Vacuna BNT162 , COVID-19 , Anticuerpos Antivirales , COVID-19/prevención & control , Vacunas contra la COVID-19 , Humanos , Huésped Inmunocomprometido , Inmunogenicidad Vacunal , Metotrexato , Estudios Prospectivos , Rituximab , SARS-CoV-2
3.
Emerg Infect Dis ; 24(2): 193-200, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-29350138

RESUMEN

We describe the frequency, demographic and clinical features, and visual outcomes of ocular syphilis infections observed during 2012-2015 at a tertiary reference center in Paris, France. Twenty-one cases (29 eyes) were identified. The occurrence of ocular syphilis increased from 1 case in 2012 to 5 cases in 2013, 6 cases in 2014, and 9 cases in 2015 (2.22-25.21/1,000 individual patients/year for the period). Among case-patients, an annual 20%-33% were co-infected with HIV. Seventy-six percent of ocular syphilis infections occurred in men who have sex with men. Seventy-five percent of case-patients had a good final visual outcome (best-corrected visual acuity >0.3 logMAR score). Visual outcome was worse for HIV-positive patients than for HIV-negative patients (p = 0.0139). At follow-up, the best visual outcomes were observed in patients whose mean time from first ocular symptom to consultation was 15 days (SD +19 days).


Asunto(s)
Infecciones Bacterianas del Ojo/epidemiología , Infecciones Bacterianas del Ojo/microbiología , Sífilis/epidemiología , Adulto , Anciano , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Estudios de Cohortes , Infecciones por VIH/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Paris/epidemiología , Estudios Retrospectivos , Sífilis/complicaciones , Sífilis/tratamiento farmacológico , Resultado del Tratamiento , Uveítis/epidemiología , Uveítis/microbiología , Adulto Joven
4.
Ann Biol Clin (Paris) ; 74(5): 597-605, 2016 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-27707674

RESUMEN

The diagnostics and follow-up of monoclonal gammopathies such as multiple myeloma require precise analysis of the monoclonal component as well as the other immunoglobulins isotypes, which might be limited by the sensitivity of standard laboratory methods. New serum biomarkers were developed for routine practice in the last decades, such as the free light chain assays and more recently the heavy/light chain assays. Studies have shown that serum free light chain measurement was useful in the identification and follow-up of pauci or nonsecretory myeloma, free light-chain multiple myeloma and AL amyloidosis. It is also an important prognostic marker for monoclonal gammopathy of undetermined significance and AL amyloidosis progression. Hevylite method enables quantitative analysis of heavy/light chain pairs of IgG, IgA and IgM immunoglobulins. This technique has a promising potential to enrich the standard analytic tools as it enables to assess the concentration and ratio of the levels of both tumor and physiological immunoglobulins (heavy/light chain pair suppression), which is not possible with serum protein electrophoresis or global quantitative analysis of immunoglobulin isotypes. This review includes the latest International myeloma working group recommendations and key data presented at the Euromedlab convention in June 2015 Paris regarding serum free light chain and heavy/light chain assays in the biological monitoring of dysglobulinemia.


Asunto(s)
Biomarcadores/sangre , Inmunoglobulinas/sangre , Monitoreo Fisiológico/métodos , Paraproteinemias/diagnóstico , Amiloidosis/sangre , Amiloidosis/diagnóstico , Estudios de Seguimiento , Humanos , Cadenas Ligeras de Inmunoglobulina/sangre , Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas , Mieloma Múltiple/sangre , Mieloma Múltiple/diagnóstico , Paraproteinemias/sangre , Guías de Práctica Clínica como Asunto , Pronóstico
5.
Crit Care ; 20(1): 171, 2016 06 05.
Artículo en Inglés | MEDLINE | ID: mdl-27262736

RESUMEN

BACKGROUND: Uncertainties about the pathophysiological processes resulting in cardiac surgery-related acute kidney injury (AKI) in infants concern the relative impact of the most prominent risk factors, the clinical relevance of changes in glomerular filtration rate vs tubular injury, and the usefulness of available diagnostic tools. Structural equation modelling could allow for the assessment of these complex relationships. METHODS: A structural model was specified using data from a prospective observational cohort of 200 patients <1 year of age undergoing cardiopulmonary bypass surgery. It included four latent variables: AKI, modelled as a construct of perioperative creatinine variation, of oliguria and of urine neutrophil gelatinase-associated lipocalin (uNGAL) concentrations; the cardiopulmonary bypass characteristics; the occurrence of a post-operative low cardiac output syndrome and the post-operative outcome. RESULTS: The model showed a good fit, and all path coefficients were statistically significant. The bypass was the most prominent risk factor, with a path coefficient of 0.820 (95 % CI 0.527-0.979), translating to a 67.2 % explanation for the risk of AKI. A strong relationships was found between AKI and early uNGAL excretion, and between AKI and the post-operative outcome, with path coefficients of 0.611 (95 % CI 0.347-0.777) and 0.741 (95 % CI 0.610-0.988), respectively. The path coefficient between AKI and a >50 % increase in serum creatinine was smaller, with a path coefficient of 0.443 (95 % CI 0.273-0.596), and was intermediate for oliguria, defined as urine output <0.5 ml kg(-1) h(-1), with a path coefficient of 0.495 (95 % CI 0.250-0.864). A path coefficient of -0.229 (95 % CI -0.319 to 0.060) suggested that the risk of AKI during the first year of life did not increase with younger age at surgery. CONCLUSIONS: These findings suggest that cardiac surgery-related AKI in infants is a translation of tubular injury, predominately driven by the cardiopulmonary bypass, and linked to early uNGAL excretion and to post-operative outcome. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01219998 . Registered 11 October 2010.


Asunto(s)
Lesión Renal Aguda/fisiopatología , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Lesión Renal Aguda/etiología , Biomarcadores/análisis , Biomarcadores/orina , Procedimientos Quirúrgicos Cardíacos/mortalidad , Procedimientos Quirúrgicos Cardíacos/estadística & datos numéricos , Puente Cardiopulmonar/efectos adversos , Puente Cardiopulmonar/estadística & datos numéricos , Creatinina/análisis , Creatinina/orina , Oxigenación por Membrana Extracorpórea/métodos , Femenino , Francia , Humanos , Recién Nacido , Lipocalina 2/análisis , Lipocalina 2/orina , Masculino , Pediatría/estadística & datos numéricos , Pediatría/tendencias , Diálisis Peritoneal/métodos , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/mortalidad , Factores de Riesgo
6.
Biochem Biophys Res Commun ; 393(4): 783-7, 2010 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-20171184

RESUMEN

We compared the apoptotic mechanism involved in U937 human monocytic cell line in presence of oxidized low-density lipoproteins (oxLDL) obtained after treatment with hypochlorous acid (HOCl) or copper (Cu). Both types of oxLDL induced U937 apoptotic cell death via the mitochondrial pathway. In contrast to HOCl-oxLDL, Cu-oxLDL induced apoptosis via a caspase-independent mechanism, with no activation of pro-caspase-3, but via the release of apoptosis inducing factor (AIF) from mitochondria. The apoptotic program of the monocyte differs depending on the mode of LDL oxidation, based on differences in the oxidatively modified components of the two oxLDL types.


Asunto(s)
Apoptosis , Lipoproteínas LDL/metabolismo , Mitocondrias/metabolismo , Monocitos/fisiología , Factor Inductor de la Apoptosis/metabolismo , Cobre/farmacología , Humanos , Ácido Hipocloroso/farmacología , Lipoproteínas LDL/farmacología , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Oxidación-Reducción , Células U937
7.
Br J Nutr ; 101(6): 852-8, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18710607

RESUMEN

Dietary intake of long-chain n-3 PUFA has been reported to decrease several markers of lymphocyte activation and modulate monocyte susceptibility to apoptosis. However, most human studies examined the combined effect of DHA and EPA using relatively high daily amounts of n-3 PUFA. The present study investigated the effects of increasing doses of DHA added to the regular diet of human healthy volunteers on lymphocyte response to tetradecanoylphorbol acetate plus ionomycin activation, and on monocyte apoptosis induced by oxidized LDL. Eight subjects were supplemented with increasing daily doses of DHA (200, 400, 800, 1600 mg) in a TAG form containing DHA as the only PUFA, for 2 weeks each dose. DHA intake dose-dependently increased the proportion of DHA in mononuclear cell phospholipids, the augmentation being significant after 400 mg DHA/d. The tetradecanoylphorbol acetate plus ionomycin-stimulated IL-2 mRNA level started to increase after ingestion of 400 mg DHA/d, with a maximum after 800 mg intake, and was positively correlated (P < 0.003) with DHA enrichment in cell phospholipids. The treatment of monocytes by oxidized LDL before DHA supplementation drastically reduced mitochondrial membrane potential as compared with native LDL treatment. Oxidized LDL apoptotic effect was significantly attenuated after 400 mg DHA/d and the protective effect was maintained throughout the experiment, although to a lesser extent at higher doses. The present results show that supplementation of the human diet with low DHA dosages improves lymphocyte activability. It also increases monocyte resistance to oxidized LDL-induced apoptosis, which may be beneficial in the prevention of atherosclerosis.


Asunto(s)
Antioxidantes/administración & dosificación , Ácidos Docosahexaenoicos/administración & dosificación , Leucocitos Mononucleares/inmunología , Análisis de Varianza , Apoptosis/efectos de los fármacos , Biomarcadores/análisis , Células Cultivadas , Suplementos Dietéticos , Relación Dosis-Respuesta a Droga , Ácidos Grasos/análisis , Humanos , Interleucina-2/genética , Activación de Linfocitos/efectos de los fármacos , Masculino , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Persona de Mediana Edad , Fosfolípidos/química , ARN Mensajero/análisis
8.
Atherosclerosis ; 200(2): 247-56, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18282575

RESUMEN

This study investigated the proapoptotic effects of oxidized low density lipoprotein (oxLDL), which plays a key role in atherogenesis, on normal fresh human monocytes isolated from peripheral blood (PBMs), on human monocyte-derived macrophages, and on U937 monocytic cell line. OxLDL were generated by hypochlorous acid (HOCl) treatment of native LDL. We demonstrated that HOCl-oxLDL (200 microg/ml) induced apoptosis in PBMs and U937 cells via the mitochondrial pathway, whereas it failed to induce apoptosis in human monocyte-derived macrophages. OxLDL-induced U937 cells apoptosis involved ROS generation, mitochondrial Bax translocation with a disruption of mitochondrial membrane potential, cytosolic liberation of cytochrome c and subsequently activation of caspases-9 and -3. The interference of ROS scavengers N-acetylcysteine and catalase with HOCl-oxLDL-induced apoptosis further supports the importance of mitochondrial ROS production in this process. Bcl-2 overexpression prevented Bax translocation whereas it failed to prevent ROS generation indicating that ROS is an upstream signal for inducing mitochondrial apoptotic damages. Because monocyte apoptosis could limit early atheroma formation, it will be interesting to identify the signaling pathway(s) induced by HOCl-oxLDL leading to ROS generation. In contrast, monocyte-derived macrophages, which resist to HOCl-oxLDL-induced oxidative stress, may promote atherosclerosis.


Asunto(s)
Apoptosis , Lipoproteínas LDL/metabolismo , Monocitos/metabolismo , Especies Reactivas de Oxígeno , Proteína X Asociada a bcl-2/metabolismo , Citocromos c/metabolismo , Humanos , Ácido Hipocloroso/farmacología , Leucocitos Mononucleares/metabolismo , Potenciales de la Membrana , Mitocondrias/metabolismo , Modelos Biológicos , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Transducción de Señal , Células U937
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...